Elena Ridloff Sells 7,400 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 7,400 shares of the stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $85.37, for a total transaction of $631,738.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Elena Ridloff also recently made the following trade(s):

• On Wednesday, April 1st, Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.42, for a total value of $392,932.00.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR traded down $0.16 during mid-day trading on Thursday, hitting $84.77. The company had a trading volume of 114,596 shares, compared to its average volume of 761,006. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00. The stock has a market cap of $6.92 billion, a price-to-earnings ratio of -23.04 and a beta of 2.20. The firm’s 50 day simple moving average is $81.01 and its two-hundred day simple moving average is $71.64.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The business had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business’s quarterly revenue was down 60.8% on a year-over-year basis. During the same period last year, the firm posted ($0.88) EPS. Equities analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KYMR. Federated Hermes Inc. acquired a new position in shares of Kymera Therapeutics in the third quarter worth about $31,622,000. Hudson Bay Capital Management LP lifted its position in shares of Kymera Therapeutics by 362.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock valued at $1,309,000 after acquiring an additional 18,134 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Kymera Therapeutics by 77.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock worth $1,007,000 after purchasing an additional 10,052 shares during the period. Candriam S.C.A. lifted its holdings in shares of Kymera Therapeutics by 24.4% in the third quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after purchasing an additional 37,536 shares in the last quarter. Finally, Frontier Capital Management Co. LLC lifted its position in shares of Kymera Therapeutics by 272.7% in the second quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after purchasing an additional 359,847 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KYMR. B. Riley Financial lifted their price target on Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. Oppenheimer raised their price objective on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. Jefferies Financial Group assumed coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They issued a “buy” rating and a $110.00 target price on the stock. Bank of America increased their target price on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Stifel Nicolaus set a $114.00 target price on shares of Kymera Therapeutics in a report on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.